Mechanistic aspects of Parkinson's disease: α-synuclein and the biomembrane

Cell Biochemistry and Biophysics

Volumn 47, Issue 2, 2007, Pages 285-299

  Beyer, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Membrane interaction; Parkinson's disease; Protein aggregation; Protein misfolding; Synuclein; Vesicles

Indexed keywords

ALPHA SYNUCLEIN; LIPID;

AMINO ACID SEQUENCE; ANIMAL; BIOPHYSICS; BRAIN; CELL MEMBRANE; CHEMISTRY; HUMAN; LEWY BODY; LIPID BILAYER; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PARKINSON DISEASE; PATHOLOGY; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; REVIEW;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANIMALS; BIOPHYSICS; BRAIN; CELL MEMBRANE; HUMANS; LEWY BODIES; LIPID BILAYERS; LIPIDS; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY;

EID: 34548313729     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-007-0014-9     Document Type: Review

References (156)

1. Shults, C. W. (2006). Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America, 103, 1661-1668.
2. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995). The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 14, 467-475.
3. Totterdell, S., & Meredith, G. E. (2005). Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience, 135, 907-913.
4. Rockenstein, E., Hansen, L. A., Mallory, M., Trojanowski, J. Q., Galasko, D., & Masliah, E. (2001). Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Research, 914, 48-56.
5. Chiba-Falek, O., Lopez, G. J., & Nussbaum, R. L. (2006). Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Movement Disorders, 21, 1703-1708.
6. Segrest, J. P., Jones, M. K., De Loof, H., Brouillette, C. G., Venkatachalapathi, Y. V., & Anantharamaiah, G. M. (1992). The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. Journal of Lipid Research, 33, 141-166.
7. Davidson, W. S., Jonas, A., Clayton, D. F., & George, J. M. (1998). Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. The Journal of Biological Chemistry, 273, 9443-9449.
8. Takeda, A., Hashimoto, M., Mallory, M., Sundsumo, M., Hansen, L., Sisk, A., & Masliah, E. (1998). Abnormal distribution of the non-Aβ component of Alzheimer's disease amyloid precursor/α-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Laboratory Investigation, 78, 1169-1177.
9. Park, J. Y., & Lansbury, P. T. Jr. (2003). β-synuclein inhibits formation of α-synuclein protofibrils: A possible therapeutic strategy against Parkinson's disease. Biochemistry, 42, 3696-3700.
10. Giese, A., Bader, B., Bieschke, J., Schaffar, G., Odoy, S., Kahle, P. J., Haass, C., & Kretzschmar, H. (2005). Single particle detection and characterization of synuclein co-aggregation. Biochemical and Biophysical Research Communications, 333, 1202-1210.
11. Maroteaux, L., Campanelli, J. T., & Scheller, R. H. (1988). Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. The Journal of Neuroscience, 8, 2804-2815.
12. Withers, G. S., George, J. M., Banker, G. A., & Clayton, D. F. (1997). Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Research. Developmental Brain Research, 99, 87-94.
13. Irizarry, M. C., Kim, T.-W., McNamara, M., Tanzi, R. E., George, J. M., Clayton, D. F., & Hyman, B. T. (1996). Characterization of the precursor protein of the non-Aβ component of senile plaques (NACP) in the human central nervous system. Journal of Neuropathology and Experimental Neurology, 55, 889-895.
14. Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van der Putten, H., Probst, A., Kremmer, E., Kretzschmar, H. A., & Haass, C. (2000). Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. The Journal of Neuroscience, 20, 6365-6373.
15. Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G., & Goedert, M. (1998). Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. The Journal of Biological Chemistry, 273, 26292-26294.
16. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2000). Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. The Journal of Neuroscience, 20, 3214-3220.
17. Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., Lu, B., & Nussbaum, R. L. (2002). Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. The Journal of Neuroscience, 22, 8797-8807.
18. Nuscher, B., Kamp, F., Mehnert, T., Odoy, S., Haass, C., Kahle, P. J., & Beyer, K. (2004). Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: A thermodynamics study. The Journal of Biological Chemistry, 279, 21966-21975.
19. Lotharius, J., & Brundin, P. (2002). Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Human Molecular Genetics, 11, 2395-2407.
20. Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Garcia Verdugo, J. M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., & Rosenthal, A. (2000). Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
21. Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., Lu, B., & Nussbaum, R. L. (2002). Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. The Journal of Neuroscience, 22, 8797-8807.
22. Chandra, S., Fornai, F., Kwon, H. B., Yazdani, U., Atasoy, D., Liu, X., Hammer, R. E., Battaglia, G., German, D. C., Castillo, P. E., & Sudhof, T. C. (2004). Double-knockout mice for alpha- and beta-synucleins: Effect on synaptic functions. Proceedings of the National Academy of Sciences of the United States of America, 101, 14966-14971.
23. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000). Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science, 287, 1265-1269.
24. Springer, W., & Kahle, P. J. (2006). Mechanisms and models of alpha-synuclein-related neurodegeneration. Current Neurology and Neuroscience Reports, 6, 432-436.
25. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., & Nussbaum, R. L. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
26. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics, 18, 106-108.
27. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D. G., & de Yebenes, J. G. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of Neurology, 55, 164-173.
28. Conway, K. A., Lee, S.-J., Rochet, J.-C., Ding, T. T., Williamson, R. E., & Lansbury, P. T. Jr. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America, 97, 571-576.
29. Choi, W., Zibaee, S., Jakes, R., Serpell, L. C., Davletov, B., Crowther, R. A., & Goedert, M. (2004). Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Letters, 576, 363-368.
30. Pandey, N., Schmidt, R. E., & Galvin, J. E. (2006). The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Experimental Neurology, 197, 515-520.
31. Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Medicine, 4, 1318-1320.
32. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., & Lansbury, P. T. Jr. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America, 97, 571-576.
33. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., Louis, J.-C., Wypych, J., Biere, A. L., & Citron, M. (1999). Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. The Journal of Biological Chemistry, 274, 9843-9846.
34. Nishioka, K., Hayashi, S., Farrer, M. J., Singleton, A. B., Yoshino, H., Imai, H., Kitami, T., Sato, K., Kuroda, R., Tomiyama, H., Mizoguchi, K., Murata, M., Toda, T., Imoto, I., Inazawa, J., Mizuno, Y., & Hattori, N. (2006). Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Annals of Neurology, 59, 298-309.
35. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D. S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D., & Langston, J. W. (2004). Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications. Annals of Neurology, 55, 174-179.
36. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., & Gwinn-Hardy, K. (2003). α-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
37. Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000). Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy of Sciences of the United States of America, 97, 13354-13359.
38. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., & Suzuki, T. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics, 25, 302-305.
39. Yamamoto, A., Friedlein, A., Imai, Y., Takahashi, R., Kahle, P. J., & Haass, C. (2005). Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. The Journal of Biological Chemistry, 280, 3390-3399.
40. Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005). Molecular pathophysiology of Parkinson's disease. Annual Review of Neuroscience, 28, 57-87.
41. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J. W., Vanacore, N., van Swieten, J. C., Brice, A., Meco, G., van Duijn, C. M., Oostra, B. A., & Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256-259.
42. Canet-Aviles, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., Baptista, M. J., Ringe, D., Petsko, G. A., & Cookson, M. R. (2004). The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proceedings of the National Academy of Sciences of the United States of America, 101, 9103-9108.
43. Shendelman, S., Jonason, A., Martinat, C., Leete, T., & Abeliovich, A. (2004). DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biology, 2, e362.
44. Tan, J. M., & Dawson, T. M. (2006). Parkin blushed by PINK1. Neuron, 50, 527-529.
45. Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P., & Gallo, K. A. (2006). LRRK2 in Parkinson's disease: Protein domains and functional insights. Trends in Neuroscience, 29, 286-293.
46. Langston, J. W., & Ballard, P. A. Jr. (1983). Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. The New England Journal of Medicine, 309, 310.
47. Thiruchelvam, M., Brockel, B. J., Richfield, E. K., Baggs, R. B., & Cory-Slechta, D. A. (2000). Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson's disease? Brain Research, 873, 225-234.
48. Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., & Di Monte, D. A. (2002). The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein. The Journal of Biological Chemistry, 277, 1641-1644.
49. Cookson, M. R. (2005). The biochemistry of Parkinson's disease. Annual Review of Biochemistry, 74, 29-52.
50. Volles, M. J., & Lansbury, P. T. Jr. (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry, 42, 7871-7878.
51. Uversky, V. N. (2003). A protein-chameleon: Conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. Journal of Biomolecular Structure & Dynamics, 21, 211-234.
52. Eriksen, J. L., Dawson, T. M., Dickson, D. W., & Petrucelli, L. (2003). Caught in the act: α-synuclein is the culprit in Parkinson's disease. Neuron, 40, 453-456.
53. Dev, K. K., Hofele, K., Barbieri, S., Buchman, V. L., & van der Putten, H. (2003). α-Synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 45, 14-44.
54. Lotharius, J., & Brundin, P. (2002). Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nature Reviews. Neuroscience, 3, 932-942.
55. Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M. (2002). Structure/function of α-synuclein in health and disease: Rational development of animal models for Parkinson's and related diseases. Journal of Neurochemistry, 82, 449-457.
56. Paleologou, K. E., Irvine, G. B., & El-Agnaf, O. M. (2005). Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochemical Society Transactions, 33, 1106-1110.
57. Fink, A. L. (2006). The aggregation and fibrillation of alpha-synuclein. Accounts of Chemical Research, 39, 628-634.
58. Uversky, V. N., Li, J., Souillac, P., Millett, I. S., Doniach, S., Jakes, R., Goedert, M., & Fink, A. L. (2002). Biophysical properties of the synucleins and their propensities to fibrillate: Inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. The Journal of Biological Chemistry, 277, 11970-11978.
59. Uversky, V. N. (2002). What does it mean to be natively unfolded? European Journal of Biochemistry, 269, 2-12.
60. Chandra, S., Chen, X., Rizo, J., Jahn, R., & Südhof, T. C. (2003). A broken α-helix in folded α-synuclein. The Journal of Biological Chemistry, 278, 15313-15318.
61. Eliezer, D., Kutluay, E., Bussell, R. Jr., & Browne, G. (2001). Conformational properties of α-synuclein in its free and lipid-associated states. Journal of Molecular Biology, 307, 1061-1073.
62. Ulmer, T. S., Bax, A., Cole, N. B., & Nussbaum, R. L. (2005). Structure and dynamics of micelle-bound human alpha-synuclein. The Journal of Biological Chemistry, 280, 9595-9603.
63. Crowther, R. A., Daniel, S. E., & Goedert, M. (2000). Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. Neuroscience Letters, 292, 128-130.
64. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., & Crowther, R. A. (2000). Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proceedings of the National Academy of Sciences of the United States of America, 97, 4897-4902.
65. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., & Lansbury, P. T. Jr. (1996). NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 35, 13709-13715.
66. Jo, E., McLaurin, J., Yip, C. M., St. George-Hyslop, P., & Fraser, P. E. (2000). α-Synuclein membrane interactions and lipid specificity. The Journal of Biological Chemistry, 275, 34328-34334.
67. Conway, K. A., Harper, J. D., & Lansbury, P. T. Jr. (2000). Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-2563.
68. George, J. M., Jin, H., Woods, W. S., & Clayton, D. F. (1995). Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron, 15, 361-372.
69. Perrin, R. J., Woods, W. S., Clayton, D. F., & George, J. M. (2000). Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. The Journal of Biological Chemistry, 275, 34393-34398.
70. Outeiro, T. F., & Lindquist, S. (2003). Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science, 302, 1772-1775.
71. Fortin, D. L., Troyer, M. D., Nakamura, K., Kubo, S., Anthony, M. D., & Edwards, R. H. (2004). Lipid rafts mediate the synaptic localization of alpha-synuclein. The Journal of Neuroscience, 24, 6715-6723.
72. Jo, E., Fuller, N., Rand, R. P., St George-Hyslop, P., & Fraser, P. E. (2002). Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein. Journal of Molecular Biology, 315, 799-807.
73. Ulmer, T. S., & Bax, A. (2005). Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. The Journal of Biological Chemistry, 280, 43179-43187.
74. Zhu, M., Li, J., & Fink, A. L. (2003). The association of {alpha}-synuclein with membranes affects bilayer structure, stability, and fibril formation. The Journal of Biological Chemistry, 278, 40186-40197.
75. Rhoades, E., Ramlall, T. F., Webb, W. W., & Eliezer, D. (2006). Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophysical Journal, 90, 4692-4700.
76. Ramakrishnan, M., Jensen, P. H., & Marsh, D. (2003). Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. Biochemistry, 42, 12919-12926.
77. Ramakrishnan, M., Jensen, P. H., & Marsh, D. (2006). Association of alpha-synuclein and mutants with lipid membranes: Spin-label ESR and polarized IR. Biochemistry, 45, 3386-3395.
78. Crowther, R. A., Jakes, R., Spillantini, M. G., & Goedert, M. (1998). Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Letters, 436, 309-312.
79. Murray, I. V., Giasson, B. I., Quinn, S. M., Koppaka, V., Axelsen, P. H., Ischiropoulos, H., Trojanowski, J. Q., & Lee, V. M. (2003). Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry, 42, 8530-8540.
80. Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, T. M., Jakala, P., Hartmann, T., Price, D. L., & Lee, M. K. (2005). Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proceedings of the National Academy of Sciences of the United States of America, 102, 2162-2167.
81. Liu, C. W., Giasson, B. I., Lewis, K. A., Lee, V. M., Demartino, G. N., & Thomas, P. J. (2005). A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson disease. The Journal of Biological Chemistry, 280, 22670-22678.
82. Campbell, B. C. V., McLean, C. A., Culvenor, J. G., Gai, W. P., Blumbergs, P. C., Jäkälä, P., Beyreuther, K., Masters, C. L., & Li, Q.-X. (2001). The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. Journal of Neurochemistry, 76, 87-96.
83. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q., & Iwatsubo, T. (1998). Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. American Journal of Pathology, 152, 879-884.
84. Madine, J., Doig, A. J., & Middleton, D. A. (2006). A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry, 45, 5783-5792.
85. Perrin, R. J., Woods, W. S., Clayton, D. F., & George, J. M. (2001). Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. The Journal of Biological Chemistry, 276, 41958-41962.
86. Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & Lee, V. M.-Y. (2000). Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science, 290, 985-989.
87. Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M.-Y., & Ischiropoulos, H. (2000). Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. The Journal of Biological Chemistry, 275, 18344-18349.
88. Necula, M., Chirita, C. N., & Kuret, J. (2003). Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. The Journal of Biological Chemistry, 278, 46674-46680.
89. Narayanan, V., & Scarlata, S. (2001). Membrane binding and self-association of alpha-synucleins. Biochemistry, 40, 9927-9934.
90. Kamp, F., & Beyer, K. (2006). Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. The Journal of Biological Chemistry, 281, 9251-9259.
91. den Jager, W. A. (1969). Sphingomyelin in Lewy inclusion bodies in Parkinson's disease. Archives of Neurology, 21, 615-619.
92. Gai, W. P., Yuan, H. X., Li, X. Q., Power, J. T. H., Blumbergs, P. C., & Jensen, P. H. (2000). In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin, and lipids in Lewy bodies. Experimental Neurology, 166, 324-333.
93. Eliezer, D., Kutluay, E., Bussell, R. Jr., & Browne, G. (2001). Conformational properties of alpha-synuclein in its free and lipid-associated states. Journal of Molecular Biology, 307, 1061-1073.
94. Bussell R. Jr., & Eliezer, D. (2001). Residual structure and dynamics in Parkinson's disease-associated mutants of α-synuclein. The Journal of Biological Chemistry, 276, 45996-46003.
95. Bussell, R. Jr., & Eliezer, D. (2003). A structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins. Journal of Molecular Biology, 329, 763-778.
96. Bertoncini, C. W., Jung, Y. S., Fernandez, C. O., Hoyer, W., Griesinger, C., Jovin, T. M., & Zweckstetter, M. (2005). From the cover: Release of long-range tertiary interactions potentiates aggregation of natively unstructured {alpha}-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 102, 1430-1435.
97. Fernandez, C. O., Hoyer, W., Zweckstetter, M., Jares-Erijman, E. A., Subramaniam, V., Griesinger, C., & Jovin, T. M. (2004). NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO Journal, 23, 2039-2046.
98. Bisaglia, M., Tessari, I., Pinato, L., Bellanda, M., Giraudo, S., Fasano, M., Bergantino, E., Bubacco, L., & Mammi, S. (2005). A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles. Biochemistry, 44, 329-339.
99. Bussell, R. Jr., Ramlall, T. F., & Eliezer, D. (2005). Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Science, 14, 862-872.
100. Aniansson, E. A. G., Wall, S. N., Almgren, M., Hoffmann, H., Kielmann, I., Ulbricht, W., Zana, R., Lang, J., & Tondre, C. (1976). Theory of the kinetics of micellar equilibria and quantitative interpretation of chemical relaxation studies of micellar solutions of ionic surfactants. The Journal of Physical Chemistry, 80, 905-922.
101. Der-Sarkissian, A., Jao, C. C., Chen, J., & Langen, R. (2003). Structural organization of α-synuclein fibrils studied by site-directed spin labeling. The Journal of Biological Chemistry, 278, 37530-37535.
102. Jao, C. C. (2004). Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. PNAS, 101, 8331-8336.
103. Bertoncini, C. W., Fernandez, C. O., Griesinger, C., Jovin, T. M., & Zweckstetter, M. (2005). Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. The Journal of Biological Chemistry, 280, 30649-30652.
104. Shibayama-Imazu, T., Okahashi, I., Omata, K., Nakajo, S., Ochiai, H., Nakai, Y., Hama, T., Nakamura, Y., & Nakaya, K. (1993). Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). Brain Research, 622, 17-25.
105. McLean, P. J., Kawamata, H., Ribich, S., & Hyman, B. T. (2000). Membrane association and protein conformation of α-synuclein in intact neurons. The Journal of Biological Chemistry, 275, 8812-8816.
106. Irizarry, M. C., Kim, T. W., McNamara, M., Tanzi, R. E., George, J. M., Clayton, D. F., & Hyman, B. T. (1996). Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. Journal of Neuropathology and Experimental Neurology, 55, 889-895.
107. Lee, H. J., Choi, C., & Lee, S. J. (2002). Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. The Journal of Biological Chemistry, 277, 671-678.
108. Zhu, M., & Fink, A. L. (2003). Lipid binding inhibits alpha-synuclein fibril formation. The Journal of Biological Chemistry, 5, 5.
109. Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D., & Nussbaum, R. L. (2002). Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. The Journal of Biological Chemistry, 277, 6344-6352.
110. Sharon, R., Goldberg, M. S., Bar-Josef, I., Betensky, R. A., Shen, J., & Selkoe, D. J. (2001). alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proceedings of the National Academy of Sciences of the United States of America, 98, 9110-9115.
111. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., & Selkoe, D. J. (2003). The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron, 37, 583-595.
112. Sharon, R., Bar-Joseph, I., Mirick, G. E., Serhan, C. N., & Selkoe, D. J. (2003). Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. The Journal of Biological Chemistry, 278, 49874-49881.
113. Lucke, C., Gantz, D. L., Klimtchuk, E., & Hamilton, J. A. (2006). Interactions between fatty acids and alpha-synuclein. Journal of Lipid Research, 47, 1714-1724.
114. Edidin, M. (2003). The state of lipid rafts: From model membranes to cells. Annual Review of Biophysics and Biomolecular Structure, 32, 257-283.
115. Heerklotz, H. (2002). Triton promotes domain formation in lipid raft mixtures. Biophysical Journal, 83, 2693-2701.
116. Kubo, S., Nemani, V. M., Chalkley, R. J., Anthony, M. D., Hattori, N., Mizuno, Y., Edwards, R. H., & Fortin, D. L. (2005). A combinatorial code for the interaction of alpha-synuclein with membranes. The Journal of Biological Chemistry, 280, 31664-31672.
117. Kim, Y. S., Laurine, E., Woods, W., & Lee, S. J. (2006). A novel mechanism of interaction between alpha-synuclein and biological membranes. Journal of Molecular Biology, 360, 386-397.
118. Wislet-Gendebien, S., D'Souza, C., Kawarai, T., St George-Hyslop, P., Westaway, D., Fraser, P., & Tandon, A. (2006). Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. The Journal of Biological Chemistry, 281, 32148-32155.
119. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., & Rosenthal, A. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
120. Sayre, L. M., Smith, M. A., & Perry, G. (2001). Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Current Medicinal Chemistry, 8, 721-738.
121. Jenner, P. (2003). Oxidative stress in Parkinson's disease. Annals of Neurology, 53(Suppl 3), S26-36; discussion S36-28.
122. Glaser, C. B., Yamin, G., Uversky, V. N., & Fink, A. L. (2005). Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochimica et Biophysica Acta, 1703, 157-169.
123. Zhu, M., Qin, Z. J., Hu, D., Munishkina, L. A., & Fink, A. L. (2006). alpha-Synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry, 45, 8135-8142.
124. Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, T., Hashimoto, M., & Masliah, E. (2000). α-Synuclein promotes mitochondrial deficit and oxidative stress. American Journal of Pathology, 157, 401-410.
125. Jenco, J. M., Rawlingson, A., Daniels, B., & Morris, A. J. (1998). Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry, 37, 4901-4909.
126. Ahn, B. H., Rhim, H., Kim, S. Y., Sung, Y. M., Lee, M. Y., Choi, J. Y., Wolozin, B., Chang, J. S., Lee, Y. H., Kwon, T. K., Chung, K. C., Yoon, S. H., Hahn, S. J., Kim, M. S., Jo, Y. H., & Min do, S. (2002). alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. The Journal of Biological Chemistry, 277, 12334-12342.
127. Payton, J. E., Perrin, R. J., Woods, W. S., & George, J. M. (2004). Structural determinants of PLD2 inhibition by alpha-synuclein. Journal of Molecular Biology, 337, 1001-1009.
128. Schmidt, A., Wolde, M., Thiele, C., Fest, W., Kratzin, H., Podtelejnikov, A. V., Witke, W., Huttner, W. B., & Soling, H. D. (1999). Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature, 401, 133-141.
129. Sidhu, A., Wersinger, C., & Vernier, P. (2004). alpha-Synuclein regulation of the dopaminergic transporter: A possible role in the pathogenesis of Parkinson's disease. FEBS Letters, 565, 1-5.
130. Cubells, J. F., Rayport, S., Rajendran, G., & Sulzer, D. (1994). Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. The Journal of Neuroscience, 14, 2260-2271.
131. Lotharius, J., & O'Malley, K. L. (2001). Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Annals of Neurology, 49, 79-89.
132. Ziv, I., Offen, D., Barzilai, A., Haviv, R., Stein, R., Zilkha-Falb, R., Shirvan, A., & Melamed, E. (1997). Modulation of control mechanisms of dopamine-induced apoptosis - a future approach to the treatment of Parkinson's disease? Journal of Neural Transmission. Supplementum, 49, 195-202.
133. Narayanan, V., Guo, Y., & Scarlata, S. (2005). Fluorescence studies suggest a role for alpha-synuclein in the phosphatidylinositol lipid signaling pathway. Biochemistry, 44, 462-470.
134. Lansbury, P. T. Jr. (1999). Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease. Proceedings of the National Academy of Sciences of the United States of America, 96, 3342-3344.
135. Goldberg, M. S., & Lansbury, P. T. Jr. (2000). Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease?. Nature Cell Biology, 2, E115-E119.
136. Rochet, J. C., Outeiro, T. F., Conway, K. A., Ding, T. T., Volles, M. J., Lashuel, H. A., Bieganski, R. M., Lindquist, S. L., & Lansbury, P. T. (2004). Interactions among alpha-synuclein, dopamine, and biomembranes: Some clues for understanding neurodegeneration in Parkinson's disease. Journal of Molecular Neuroscience, 23, 23-34.
137. Caughey, B., & Lansbury, P. T. Jr. (2003). Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annual Review of Neuroscience, 26, 267-298.
138. Rochet, J. C., Conway, K. A., & Lansbury, P. T. Jr. (2000). Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry, 39, 10619-10626.
139. Volles, M. J., Lee, S.-J., Rochet, J.-C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., & Lansbury, P. T. Jr. (2001). Vesicle permeabilization by protofibrillar α-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 40, 7812-7819.
140. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., & Lansbury, P. T. Jr. (2002). Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. Journal of Molecular Biology, 322, 1089-1102.
141. Ding, T. T., Lee, S. J., Rochet, J. C., & Lansbury, P. T. Jr. (2002). Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry, 41, 10209-10217.
142. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., & Lansbury, P. T. Jr. (2002). Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature, 418, 291.
143. Lashuel, H., & Grillo-Bosch, D. (2005). In vitro preparation of prefibrillar intermediates of Amyloid-β and α-Synuclein. In E. Sigurdsson (Ed.), Amyloid Proteins (Vol. 299, pp. 19-33). Totowa, NJ: Humana Press.
144. Volles, M. J., & Lansbury, P. T. Jr. (2002). Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry, 41, 4595-4602.
145. Lashuel, H. A., Hartley, D. M., Petre, B. M., Wall, J. S., Simon, M. N., Walz, T., & Lansbury, P. T. Jr. (2003). Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. Journal of Molecular Biology, 332, 795-808.
146. Haass, C., & Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nature Reviews. Molecular Cell Biology, 8, 101-112.
147. Conway, K. A., Rochet, J. C., Bieganski, R. M., & Lansbury, P. T. Jr. (2001). Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 294, 1346-1349.
148. Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M. (2005). Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. The Journal of Biological Chemistry, 280, 21212-21219.
149. Xu, J., Kao, S. Y., Lee, F. J., Song, W., Jin, L. W., & Yankner, B. A. (2002). Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nature Medicine, 8, 600-606.
150. Mazzulli, J. R., Mishizen, A. J., Giasson, B. I., Lynch, D. R., Thomas, S. A., Nakashima, A., Nagatsu, T., Ota, A., & Ischiropoulos, H. (2006). Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. The Journal of Neuroscience, 26, 10068-10078.
151. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489.
152. Glabe, C. G. (2006). Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiology of Aging, 27, 570-575.
153. Glabe, C. G., & Kayed, R. (2006). Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology, 66, S74-78.
154. Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., & Glabe, C. G. (2004). Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. The Journal of Biological Chemistry, 279, 46363-46366.
155. Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., Kagan, B., Ghiso, J., & Lal, R. (2005). Amyloid ion channels: A common structural link for protein-misfolding disease. Proceedings of the National Academy of Sciences of the United States of America, 102, 10427-10432.
156. Kagan, B. L., Hirakura, Y., Azimov, R., Azimova, R., & Lin, M. C. (2002). The channel hypothesis of Alzheimer's disease: Current status. Peptides, 23, 1311-1315.